OPCML: A Promising Biomarker and Therapeutic Avenue

Trends Cancer. 2019 Aug;5(8):463-466. doi: 10.1016/j.trecan.2019.06.002. Epub 2019 Jun 28.

Abstract

Opioid-binding protein/cell adhesion molecule (OPCML) is expressed in many tissues and localizes to the plasma membrane. It is a putative tumor suppressor that acts on receptor tyrosine kinases (RTKs), influencing cell cycle arrest, apoptosis, and migration. Its expression is silenced epigenetically in cancer, inferring potential diagnostic, prognostic, and therapeutic roles.

Keywords: cancer; diagnostic; methylation; prognostic; therapeutic; tumor suppressor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Carcinogenesis / genetics
  • Cell Adhesion Molecules / genetics*
  • Cell Adhesion Molecules / metabolism
  • Cell Adhesion Molecules / therapeutic use
  • Cell Membrane / metabolism
  • CpG Islands / genetics
  • DNA Methylation / drug effects
  • Epigenesis, Genetic / drug effects
  • GPI-Linked Proteins / genetics
  • GPI-Linked Proteins / metabolism
  • GPI-Linked Proteins / therapeutic use
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Prognosis
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Survival Rate
  • Tumor Suppressor Proteins / genetics*
  • Tumor Suppressor Proteins / metabolism
  • Tumor Suppressor Proteins / therapeutic use

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cell Adhesion Molecules
  • GPI-Linked Proteins
  • OPCML protein, human
  • Tumor Suppressor Proteins
  • Receptor Protein-Tyrosine Kinases